Ligand Pharmaceuticals Incorporated
NASDAQ:LGNDBiotechnology
+$2.89 today
- Market cap
- $5.98B
- Beta
- 1.04
- P/E (TTM)
- 34.4
- EPS (TTM)
- $7.72
Volume 0.38M
Average 0.22M
LGND Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Ligand Pharmaceuticals IncorporatedNASDAQ: LGND
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $14.67M rose 123.4% year over year, ahead of the -38.1% change in trailing-twelve-month research & development. Sequentially, it rose 582.9% from the prior quarter. Over 3 fiscal years it compounded at +31.0% a year.
Context
- Research & development amounted to 30.3% of revenue in FY2025, up 17.5 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +123.4% holds above the trailing-twelve-month pace of -38.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 81.18M USD
- Year-over-year change
- +278.9%
- 4-year CAGR
- +26.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 81.18M | +278.9% |
| FY2024 | 2024-12-31 | 21.43M | -12.7% |
| FY2023 | 2023-12-31 | 24.54M | -32.0% |
| FY2022 | 2022-12-31 | 36.08M | +12.4% |
| FY2021 | 2021-12-31 | 32.11M | — |
Research & Development vs competitors
How LGND compares with its peers on the latest reported figures
- LGND's LTM Jun 2026 research & development of $41.35M is the 9th highest of the 10 companies compared; the peer median is $2.15B.
- Its year-over-year change of -38.1% is the lowest of 9, against a peer median of +8.0%.
- Research & development amounts to 14.2% of revenue for LGND, versus a peer median of 21.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $11.05B | +7.0% | -3.0% | 17.3% | |
| LTM Jun 2026 | $10.72B | +3.1% | +1.5% | 21.8% | |
| LTM Sep 2026 | $9.96B | -25.0% | +11.8% | 15.1% | |
| LTM Jun 2026 | $7.64B | +19.3% | +16.3% | 20.0% | |
| LTM Jun 2026 | $2.15B | +9.1% | +8.9% | 37.0% | |
| LTM Jun 2026 | $1.78B | — | -34.5% | 43.1% | |
| LTM Jul 2026 | $824.32M | -6.8% | -2.6% | 33.8% | |
| LTM Jun 2026 | $197.76M | +15.5% | -13.1% | 21.0% | |
| LTM Jun 2026 | $41.35M | -38.1% | +31.0% | 14.2% | |
| LTM Mar 2026 | $36.54M | +41.7% | -17.9% | 12.2% | |
| Peer median (excluding LGND) | $2.15B | +8.0% | -2.6% | 21.0% | |
Competitors are the stored peer set for LGND. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 241.54M | 196.25M | 131.31M | 167.13M | 268.09M |
| Cost of Revenue | 62.18M | 52.83M | 35.05M | 11.07M | 6.59M |
| Gross Profit | 179.37M | 143.42M | 96.27M | 156.06M | 261.5M |
| Gross Margin | 74.3% | 73.1% | 73.3% | 93.4% | 97.5% |
| Research & Development | 32.11M | 36.08M | 24.54M | 21.43M | 81.18M |
| Selling, General & Admin | 46.79M | 70.06M | 52.79M | 78.65M | 92.45M |
| Operating Expenses | 75.52M | 140.38M | 84.32M | 178.67M | 214.3M |
| Depreciation & Amortization | 50.95M | 43.39M | 36.52M | 35.24M | 33.78M |
| EBITDA | 142.77M | 81.2M | 100.84M | 40.79M | 192.74M |
| EBITDA Margin | 59.1% | 41.4% | 76.8% | 24.4% | 71.9% |
| Operating Income | 103.85M | 3.04M | 11.94M | (22.61M) | 47.2M |
| Operating Margin | 43.0% | 1.5% | 9.1% | -13.5% | 17.6% |
| Interest Income | 886K | 2.05M | 7.71M | 8.06M | 13.66M |
| Interest Expense | 19.62M | 1.8M | 656K | 3.04M | 4.72M |
| Other Income / Expenses | (31.65M) | 32.97M | 51.72M | 25.12M | 111.76M |
| Income Before Tax | 72.21M | 36.01M | 63.66M | 2.52M | 158.96M |
| Pre-Tax Margin | 29.9% | 18.4% | 48.5% | 1.5% | 59.3% |
| Income Tax Expense | (4.15M) | 41.23M | 9.84M | 6.55M | 34.51M |
| Net Income | 57.14M | (33.36M) | 52.15M | (4.03M) | 124.45M |
| Net Margin | 23.7% | -17.0% | 39.7% | -2.4% | 46.4% |
| EPS (Basic) | 3.46 | (1.98) | 3.02 | (0.22) | 6.44 |
| EPS (Diluted) | 3.34 | (1.98) | 2.94 | (0.22) | 6.13 |
| Weighted Avg Shares | 16.63M | 16.87M | 17.3M | 18.29M | 19.34M |
| Weighted Avg Shares (Diluted) | 17.25M | 16.87M | 17.76M | 18.29M | 20.29M |
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
Intrinsic Alpha fair value
Locked
Current Price
$298.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.